Impact of Bevacizumab on Experimentally Induced Endometriotic Lesions: Angiogenesis, Invasion, Apoptosis, and Cell Proliferation

Zani, Ana Carolina Tagliatti; Valério, Fernando Passador; Meola, Juliana; Silva, Alfredo Ribeiro Da; Nogueira, Antônio Alberto; Candido-dos-Reis, Francisco José; Poli-Neto, Omero Benedicto; Silva, Júlio César Rosa e

doi:10.1007/s43032-020-00213-7

Cited by 8 publications

(7 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared to the EMs group without resveratrol treatment (Figures 1(h) and 1(i) ), significant reduction of lesion size was shown in both the Res-med groups (medium dose of resveratrol) and Res-high groups (high dose of resveratrol) ( Figure 1(j) ). The pathological lesions of EMs are typically characterized by the histological accumulation of endometrial epithelial, glandular tubes, and significant invasive growth [ 23 , 24 ]. Histochemical staining ( Figure 1(k) ) showed that resveratrol treatment led to both significant decreases in glandular tubes ( Figure 1(l) ) and endometrial epithelial thickness ( Figure 1(m) ) in both the Res-med groups and Res-high groups, compared to the EMs group without resveratrol treatment.…”

Section: Resultsmentioning

confidence: 99%

“…Compared to the EMs group without resveratrol treatment (Figures 1(h) and 1(i)), significant reduction of lesion size was shown in both the Res-med groups (medium dose of resveratrol) and Reshigh groups (high dose of resveratrol) (Figure 1(j)). The pathological lesions of EMs are typically characterized by the histological accumulation of endometrial epithelial, glandular tubes, and significant invasive growth [23,24]. Histochemical staining (Figure 1(k)) showed that resveratrol treatment led to both significant decreases in glandular tubes (Figure 1 As the occurrence of EMs had been previously shown to be related to cell adhesion, angiogenesis, and apoptosis in a mouse model, as related to the expression of specific genes including MMP-2, ICAM-1, VEGF, and BCL-2 [9,24,25], we extracted mRNA and protein from lesion tissues of model rats to analyze any expression alterations associated with resveratrol.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Lipidomic Alterations and PPARα Activation Induced by Resveratrol Lead to Reduction in Lesion Size in Endometriosis Models

Chen

Wang

Lin

et al. 2021

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Endometriosis is an estrogen-dependent chronic inflammatory disease that affects approximately 10% of women of reproductive age and up to 50% of women with infertility. The heterogeneity of the disease makes accurate diagnosis and treatment a clinical challenge. In this study, we generated two models of endometriosis: the first in rats and the second using human ectopic endometrial stromal cells (HEcESCs) derived from the lesion tissues of endometriosis patients. We then applied resveratrol to assess its therapeutic potential. Resveratrol intervention had significant efficacy to attenuate lesion size and to rectify aberrant lipid profiles of model rats. Lipidomic analysis revealed significant lipidomic alterations, including notable increases of sphingolipids and decreases of both glycerolipids and most phospholipids. Upon resveratrol application, both proliferation capacity and invasiveness parameters decreased, and the early apoptosis proportion increased for HEcESCs. The activation of PPARα was also noted as a factor potentially contributing to recovery from endometriosis in both models. Our study provides valuable insight into the mechanisms of resveratrol in endometriosis and therefore strengthens the potential for optimizing resveratrol treatment for this disease.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Compared to the EMs group without resveratrol treatment (Figures 1(h) and 1(i)), significant reduction of lesion size was shown in both the Res-med groups (medium dose of resveratrol) and Reshigh groups (high dose of resveratrol) (Figure 1(j)). The pathological lesions of EMs are typically characterized by the histological accumulation of endometrial epithelial, glandular tubes, and significant invasive growth [23,24]. Histochemical staining (Figure 1(k)) showed that resveratrol treatment led to both significant decreases in glandular tubes (Figure 1 As the occurrence of EMs had been previously shown to be related to cell adhesion, angiogenesis, and apoptosis in a mouse model, as related to the expression of specific genes including MMP-2, ICAM-1, VEGF, and BCL-2 [9,24,25], we extracted mRNA and protein from lesion tissues of model rats to analyze any expression alterations associated with resveratrol.…”

Section: Resultsmentioning

confidence: 99%

Lipidomic Alterations and PPARα Activation Induced by Resveratrol Lead to Reduction in Lesion Size in Endometriosis Models

Chen

Wang

Lin

et al. 2021

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

show abstract

“…Animal experiments already showed beneficial effects both in the treatment and prophylaxis of endometriosis relapse (16)(17)(18)(19)(20)(21). The effect of vascular endothelial growth factor inhibition on the volume of endometrial implants was described by all these authors.…”

Section: Discussionmentioning

confidence: 99%

Antiangiogenic Therapy as a New Strategy in the Treatment of Endometriosis? The First Case Report

et al. 2021

View full text Add to dashboard Cite

Angiogenesis plays a pivotal role in implantation and development of ectopic endometrial lesions. Thus, the potential usefulness of anti-angiogenic therapies has been speculated. Several reports describe their usefulness in animal models. Nonetheless this therapy has not been tested on humans yet. Here we report the outcome of a patient treated for a severe endometriosis with Bevacizumab (Avastin®), a monoclonal antibody directed against the vascular endothelial growth (VEGF). After a first-look laparoscopy with confirmatory biopsies was performed, three doses of Bevacizumab at 2-week intervals were administered. The therapy showed a well-tolerated profile and the prompt disappearance of the therapy-refractory chronic dysmenorrhea. A suppression of metabolic activity at the PET-scan compared to the basal one performed at diagnosis was also recorded. Furthermore, compared to the diagnostic biopsies prior the treatment, we documented a shift in the hormonal receptors profile toward a higher expression of progesterone and estrogen receptors in the endometriotic lesions.

show abstract

“…Numerous factors, including immunoreactions, inflammation and angiogenesis, contribute toward the development and progression of endometriosis (12). Therapeutically, the formation and progression of endometriosis may be inhibited by regulating these factors (13,14). Given the difficulties and limits to reflecting the integrity of biological processes, including endometriosis, in isolated cells, a rat endometriosis model was utilized in this study (10).…”

Section: Discussionmentioning

confidence: 99%

Rosiglitazone affects the progression of surgically‑induced endometriosis in a rat model

et al. 2020

View full text Add to dashboard Cite

Impact of Bevacizumab on Experimentally Induced Endometriotic Lesions: Angiogenesis, Invasion, Apoptosis, and Cell Proliferation

Cited by 8 publications

References 34 publications

Lipidomic Alterations and PPARα Activation Induced by Resveratrol Lead to Reduction in Lesion Size in Endometriosis Models

Lipidomic Alterations and PPARα Activation Induced by Resveratrol Lead to Reduction in Lesion Size in Endometriosis Models

Antiangiogenic Therapy as a New Strategy in the Treatment of Endometriosis? The First Case Report

Rosiglitazone affects the progression of surgically‑induced endometriosis in a rat model

Contact Info

Product

Resources

About